Category: Baxano Surgical
SafeStitch Medical lures Joseph Slattery to be its new CFO from Baxano, who names former Talecris Biotherapeutics exec Timothy Shannon as interim replacement.
Baxano fails to meet Wall Streets expectations during its 2nd quarter of 2013, during which the company reinvented itself as Baxano Surgical.
Baxano Surgical closes the books, without admitting wrong-doing, on a Justice Dept. investigation over allegations of healthcare fraud.
Covidien's doubling down in emerging markets yet again, looking to invest in Brazil, South Africa and Mexico and other high-growth regions in hopes of hitting $2 billion in emerging market revenue "as soon as possible."
Medical device giant Covidien is doubling down on emerging markets, expanding an investment program that the company had, at one point, thought would be over by the end of 2013.
Oncology diagnostics company On-Q-ity folds up its tents after an unsuccessful, 3-year bid to develop personalized cancer diagnostics – and burning through $26 million in venture capital backing.
On-Q-ity, which raised a $26 million Series A round back in December 2009, quietly folded its tents last year after an unsuccessful bid to develop its technology for personalized cancer detection.
Bruce Booth, a partner at Atlas Ventures, 1 of the VC shops that backed the company (and a member of On-Q-ity's board), detailed the reasons behind the decision this week on his blog, Life Sci VC.